GB004 in Adult Subjects With Active Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

December 17, 2019

Study Completion Date

December 17, 2019

Conditions

Ulcerative Colitis

Interventions

DRUG

GB004

GB0004 high dose

DRUG

Placebo

DRUG

GB004

GB004 low dose

Trial Locations (3)

Delta Research Partners, Monroe

Arensia Exploratory Medicine, Tbilisi

"PMSI Republican Clinical Hospital Timofei Mosneaga", Chisinau

All Listed Sponsors

lead

GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

INDUSTRY

NCT03860896 - GB004 in Adult Subjects With Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter